Bushra Mustafa Salman, Omar Ayaad, Rawan Ibrahim, Manal Salim AlHatrushi, Mohamad Majed, Razzan Al Zadjali, Zainab Abdullah AlTobi, Abier Atabani, Ghalia Mubarak AlHasani, Malouk Nasser AlMusheifri, Mohamed Ibrahim El Kholy, Sara Al Sheedi, Nabiha Said AlHasni, Amna Khamis Al-Hashar, Huda Shinoon Al-Awaisi, Khalid Al-Baimani
{"title":"Enhancing Medication Safety: Reducing Administration Errors in Oncology Setting.","authors":"Bushra Mustafa Salman, Omar Ayaad, Rawan Ibrahim, Manal Salim AlHatrushi, Mohamad Majed, Razzan Al Zadjali, Zainab Abdullah AlTobi, Abier Atabani, Ghalia Mubarak AlHasani, Malouk Nasser AlMusheifri, Mohamed Ibrahim El Kholy, Sara Al Sheedi, Nabiha Said AlHasni, Amna Khamis Al-Hashar, Huda Shinoon Al-Awaisi, Khalid Al-Baimani","doi":"10.31557/APJCP.2025.26.1.269","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.</p><p><strong>Methods: </strong>The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions. Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology. Ethical clearance was obtained from the Institutional Review Board.</p><p><strong>Results: </strong>The results showed significant reductions were observed in both medication error and medication administration error rates following the implementation of interventions. Specifically, the medication error rate decreased from 12.59 in the Second Quarter of 2022 (pre-intervention) to 5.26 in the Fourth Quarter of 2023 (post-intervention), with an overall ANOVA F-value of 9.2950 (p = 0.035). Similarly, the medication administration error rate declined from 5.39 to 1.29 over the same period, resulting in an ANOVA F-value of 8.2320 (p = 0.044).</p><p><strong>Conclusion: </strong>The study indicates a significant improvement in patient safety outcomes following the intervention implementation, underscoring the effectiveness of the interventions in reducing medication errors and administration errors.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 1","pages":"269-277"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.1.269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Enhancing Medication Safety: Reducing Administration Errors in Oncology Setting.
Purpose: This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.
Methods: The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions. Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology. Ethical clearance was obtained from the Institutional Review Board.
Results: The results showed significant reductions were observed in both medication error and medication administration error rates following the implementation of interventions. Specifically, the medication error rate decreased from 12.59 in the Second Quarter of 2022 (pre-intervention) to 5.26 in the Fourth Quarter of 2023 (post-intervention), with an overall ANOVA F-value of 9.2950 (p = 0.035). Similarly, the medication administration error rate declined from 5.39 to 1.29 over the same period, resulting in an ANOVA F-value of 8.2320 (p = 0.044).
Conclusion: The study indicates a significant improvement in patient safety outcomes following the intervention implementation, underscoring the effectiveness of the interventions in reducing medication errors and administration errors.
期刊介绍:
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.